免疫系统
肿瘤微环境
生物利用度
细胞因子
免疫疗法
癌症研究
药理学
药物输送
CD8型
医学
化学
免疫学
有机化学
作者
Lili Niu,Yao Liu,Nannan Li,Yan Wang,Lin Kang,Xiaomin Su,Ce Xu,Z. Sun,Weicong Sang,Jianping Xu,Huishu Guo,Shun Shen
标识
DOI:10.1016/j.ijpharm.2024.123810
摘要
Transforming growth factor β (TGF–β), a versatile immunosuppressive cytokine, has gained increasing attention as a potential target for cancer immunotherapy. However, current strategies are constrained by tumor heterogeneity and drug resistance. Therapeutic probiotics, such as Escherichia coli Nissle1917 (EcN), not only regulate the gut microbiota to increase beneficial bacteria with anti-tumor effects, but also modulate immune factors within the body, thereby enhancing immunity. In this study, we developed an oral microgel delivery system of EcN@(CS–SA)2 by electrostatic interaction between chitosan (CS) and sodium alginate (SA), aiming to enhance its bioavailability in the gastrointestinal tract (GIT). Notably, EcN@(CS–SA)2 microgel showed a synergistic enhancement of the anti-tumor efficacy of Galunisertib (Gal, a TGF–β inhibitor) by inducing apoptosis and immunogenic cell death (ICD) in tumor cells, as well as promoting increased infiltration of CD8+ T cells into the tumor microenvironment (TME).
科研通智能强力驱动
Strongly Powered by AbleSci AI